David M Davies
Overview
Explore the profile of David M Davies including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Muliaditan T, Halim L, Whilding L, Draper B, Achkova D, Kausar F, et al.
Cell Rep Med
. 2022 Jan;
2(12):100457.
PMID: 35028604
Second generation (2G) chimeric antigen receptors (CARs) contain a CD28 or 41BB co-stimulatory endodomain and elicit remarkable efficacy in hematological malignancies. Third generation (3G) CARs extend this linear blueprint by...
12.
Kosti P, Opzoomer J, Larios-Martinez K, Henley-Smith R, Scudamore C, Okesola M, et al.
Cell Rep Med
. 2021 May;
2(4):100227.
PMID: 33948568
Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR...
13.
Davies D, Maher J
Cancer Cell
. 2021 Jan;
39(2):138-140.
PMID: 33417830
CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue...
14.
Thayaparan T, Petrovic R, Achkova D, Zabinski T, Davies D, Klampatsa A, et al.
Oncoimmunology
. 2017 Dec;
6(12):e1363137.
PMID: 29209570
Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors...
15.
Whilding L, Parente-Pereira A, Zabinski T, Davies D, Petrovic R, Kao Y, et al.
Mol Ther
. 2017 Sep;
25(10):2427.
PMID: 28958577
No abstract available.
16.
Post M, Cuapio A, Osl M, Lehmann D, Resch U, Davies D, et al.
Front Immunol
. 2017 May;
8:535.
PMID: 28555134
We identified as the most highly upregulated transcription factor gene during differentiation of human CD34 cord blood progenitor cells to CD56 natural killer (NK) cells. ZNF683/HOBIT mRNA was preferentially expressed...
17.
Klampatsa A, Achkova D, Davies D, Parente-Pereira A, Woodman N, Rosekilly J, et al.
Cancer Lett
. 2017 Feb;
393:52-59.
PMID: 28223167
Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one ErbB family member was expressed in...
18.
Whilding L, Parente-Pereira A, Zabinski T, Davies D, Petrovic R, Kao Y, et al.
Mol Ther
. 2017 Jan;
25(1):259-273.
PMID: 28129120
Expression of the αvβ6 integrin is upregulated in several solid tumors. In contrast, physiologic expression of this epithelial-specific integrin is restricted to development and epithelial re-modeling. Here, we describe, for...
19.
Maher J, Wilkie S, Davies D, Arif S, Picco G, Julien S, et al.
Immunity
. 2016 Nov;
45(5):945-946.
PMID: 27851917
We read with interest the manuscript by June and colleagues published recently in Immunity in which they describe targeting of aberrantly glycosylated tumor-associated cell membrane mucin MUC1 using chimeric antigen...
20.
van der Stegen S, Davies D, Wilkie S, Foster J, Sosabowski J, Burnet J, et al.
J Immunol
. 2013 Sep;
191(9):4589-98.
PMID: 24062490
The ErbB network is dysregulated in many solid tumors. To exploit this, we have developed a chimeric Ag receptor (CAR) named T1E28z that targets several pathogenetically relevant ErbB dimers. T1E28z...